Form 4: Ionis Director Sells 5,000 Shares Under 10b5-1 Plan

Ionis Pharmaceuticals Director B. Lynne Parshall sold 5,000 shares of common stock for approximately $71.74 per share under a pre-arranged trading plan.

Summary

• B. Lynne Parshall, a Director at Ionis Pharmaceuticals Inc. (IONS), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of common stock.
• The shares were sold at a weighted average price of $71.7443 per share.
• The total value of the transaction is approximately $358,721.50.
• The sale was executed on October 15, 2025.
• Following this transaction, Ms. Parshall directly owns 61,344 shares of Ionis common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on May 6, 2025.
• Individual sale prices for the shares ranged from $71.265 to $72.06.

Sentiment

Score: 4

Explanation: A director's sale of common stock, even under a Rule 10b5-1 plan, can be perceived as a slightly negative signal by the market, though the impact is often mitigated by the pre-planned nature of the transaction and the remaining significant holdings.

Negatives

• A director sold 5,000 shares of common stock, which could be interpreted by some investors as a move to diversify holdings or a slight lack of confidence, despite being under a pre-arranged plan.

Risks

• Insider sales, even when conducted under a Rule 10b5-1 plan, can sometimes be perceived negatively by the market, potentially leading to short-term downward pressure on the stock price if investors interpret it as a signal from management.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sale of 5,000 shares of common stock by Director B. Lynne Parshall to the open market.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially influencing short-term sentiment, though the pre-planned nature of the transaction typically lessens this impact.

Key Dates

Recommendation

The filing reports a routine insider sale by a director under a pre-arranged 10b5-1 trading plan. While insider sales can sometimes be a negative signal, this transaction's pre-planned nature and the director's continued significant holdings suggest it is likely for personal financial planning or diversification rather than a lack of confidence in the company's future. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Sale, Director, B. Lynne Parshall, 10b5-1 Plan